Fennec Pharmaceuticals Inc. (FENC) earnings
FENC earnings moved a median of -0.72% by the close. Quarterly and annual FENC reports and results, each read against the price at its own news timestamp. Back to the FENC overview →
31 measured FENC earnings events.
Where these FENC earnings landedvs 31 measured FENC earnings reactions
| Middle 50% of FENC earnings reactions | -3.04% to +1.21% |
|---|---|
| Median reaction (to close) | -0.72% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 FENC earnings events with a measured close landed between -3.04% and +1.21%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q FENNEC PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -1.57% | -3.06% | |
| Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +2.49% | +5.10% | |
| Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 | Press release | +0.00% | +2.94% | |
| Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | +10.56% | +28.33% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +3.90% | +5.63% | |
| Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 | Press release | -0.84% | -3.36% | |
| Form 10-K FENNEC PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -2.23% | -1.03% | |
| Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 | Press release | +0.71% | -3.11% | |
| Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update | Press release | +11.16% | +18.97% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +0.35% | -3.02% | |
| Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 | Press release | +0.00% | -0.72% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -0.71% | +3.48% | |
| Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -2.04% | -1.97% | |
| Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 | Press release | +0.00% | -4.03% | |
| Form 10-K FENNEC PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.00% | -0.46% | |
| Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 | Press release | — | +1.03% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -1.14% | -2.52% | |
| Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -5.12% | -7.04% | |
| Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 | Press release | +1.01% | -2.24% | |
| Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | -6.41% | +1.39% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | -1.18% | -9.81% | |
| Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 | Press release | +0.00% | +0.88% | |
| Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | -12.53% | -18.63% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -6.07% | -10.86% | |
| Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 | Press release | +2.05% | +0.22% | |
| Form 10-K FENNEC PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.59% | -1.90% | |
| Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update | Press release | -2.81% | -2.81% | |
| Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 | Press release | -1.65% | +0.92% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -0.26% | |
| Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update | Press release | -2.36% | +1.40% | |
| Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023 | Press release | -0.15% | +1.03% |
Keep exploring
More FENC: analyst actions → · SEC filings → · FENC overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SOPHIRIS BIO INC (SPHS) | 366 | -0.23% | 37% |
| EISAI CO S/ADR (ESALY) | 365 | 0.00% | 33% |
| RadNet, Inc. (RDNT) | 364 | +0.09% | 53% |
| Aerpio Pharmaceuticals, Inc (ARPO) | 363 | 0.00% | 32% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.